Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience
Authors:
Open Access
- 2 June 2025
- journal article
- Published by Elsevier in European Urology Oncology
- Vol. 8 (6) , 1513-1523
Abstract
No abstract availableKeywords
Funding Information
- European Commission (CUP UNIFG D73C22001230006)
- European Commission (PNRR\u2014M4C2-I1.3)
- Regione Puglia
- Ministero dell'Istruzione e del Merito
- FP7 Coordination of Research Activities
- Università degli Studi di Foggia
- Ministero della Salute (PNRR-MR1-2023-12377571)
- Ministero della Salute (PNRR-M6/C2)
- Ministero dell’Istruzione, dell’Università e della Ricerca (CUP D74C22000040002)
- Ministero dell’Istruzione, dell’Università e della Ricerca (CUP D53D23014290006)
This publication has 33 references indexed in Scilit:
- Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancerWorld Journal of Urology, 2024
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designThe Lancet, 2022
- The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory RevisitedEuropean Urology, 2021
- Clinical features of neuroendocrine prostate cancerEuropean Journal of Cancer, 2019
- In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH DatabaseEuropean Urology Focus, 2017
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyEuropean Urology, 2017
- HGVS Recommendations for the Description of Sequence Variants: 2016 UpdateHuman Mutation, 2016
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2015
- The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate CancerEuropean Urology, 2014
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013